Project Grant R56HL175516
Award Date
8/1/24
Completion Date
7/31/25
Dollars Obligated
$834K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
West Hollywood, CA 90048, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $298,368 Project Grant to Link Medical LLC to develop a novel catheter-based device for treating mitral valve regurgitation. The goal is to restore proper valve function in patients with functional mitral regurgitation by repositioning the valve chords using a constraining band. This project will optimize the device design and procedure through bench testing,...
The National Heart Lung and Blood Institute (NHLBI) awarded a $810,650 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to Cedars-Sinai Medical Center. The funding will support the development and validation of an artificial intelligence (AI)-enabled algorithm to characterize fibrotic and calcific aortic valve tissue from computed tomography angiography (CTA) scans. The goal is to predict rapid aortic valve disease progression and create an AI-powered risk score to predict...
This $974,043 federal Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports early cardiac biomarker research for Duchenne muscular dystrophy (DMD) at Cedars-Sinai Medical Center in West Hollywood, CA. The award period runs from September 1, 2025 to August 31, 2029 and will fund advanced biomedical investigations into inflammation and remodeling biomarkers to improve understanding and treatment of cardiovascular complications...
The University of California, Davis received a $400,417 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to conduct research on cardiac regenerative therapy using gene-edited stem cells. The goal is to improve transplantation outcomes and address the critical role of inflammation-induced cell death that impedes current cardiac stem cell therapies. The research aims to develop new treatments for end-stage heart failure, a...
UNRAVELING THE MECHANISM OF HEART FAILURE IN HYPERTROPHIC CARDIOMYOPATHY WITH EXERCISE CMR - PROJECT SUMMARY HYPERTROPHIC CARDIOMYOPATHY (HCM) IS THE MOST COMMON GENETIC HEART DISEASE, WITH HEART FAILURE (HF) BEING THE MOST COMMON ADVERSE COMPLICATION AND CAUSE OF DEATH. HCM COMPRISES TWO DISTINCT PHENOTYPES: WITH AND WITHOUT LEFT VENTRICULAR OUTFLOW TRACT (LVOT) OBSTRUCTION. THERE ARE ESTABLISHED PHARMACOTHERAPY AND SURGICAL OPTIONS FOR TREATING OBSTRUCTIVE HCM PATIENTS. MAVACAMTEN (I.E.,...
This federal Project Grant award, worth $827,356.00, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The funding supports a prospective study to determine the imaging response to immune suppressant therapy in patients with active cardiac sarcoidosis. The study aims to establish quantitative thresholds for imaging parameters, such as FDG uptake on PET and advanced cardiac MRI measures, that are associated with...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the Cardiovascular Diseases Research program (CFDA 93.837), provides $2,027,737 to 3DT Holdings, LLC to develop and validate a machine learning-based software tool for optimizing the placement of the MitraClip device in patients with mitral regurgitation. The key products and services to be delivered include: Generating a dataset of over 5,000 finite element models from patient images to simulate...
This federal Project Grant award, valued at $181,392.00 and provided by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research), supports research to optimize surgical procedures for congenital aortic valve disease. The Principal Investigator, Dr. Alexander D. Kaiser, will leverage a novel computational modeling framework to (1) simulate and optimize the leaflet geometry of bicuspidization repair and bioprinted valve replacement procedures, (2) validate the...
This Project Grant award, totaling $1,862,169.00 and funded by the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 Cardiovascular Diseases Research, supports a comprehensive research initiative to investigate the mechanism of myocardial fibrosis induced by mitral valve prolapse (MVP). The research project, led by The General Hospital Corporation (doing business as Massachusetts General Hospital), aims to elucidate the link between altered mechanical forces caused by MVP and...
This $580,863 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Program (CFDA 93.837), supports research to develop improved cardiac regenerative therapies using engineered human cardiac organoids. The key products and services being delivered include: Optimizing the electrical properties and surface roughness of silicon nanowires incorporated into the cardiac organoids to enhance their interaction with human pluripotent stem...